Stopped: Company decision after projects re-evaluation, taken before the study initiation.
The main aim of this study is to learn about metachromatic leukodystrophy (MLD) in children and teenagers in Spain. This includes checking the number of new MLD cases and the frequency of children with MLD in 2022 in Spain. There is no treatment involved in this study. Participants' data will be taken from their medical records (charts), which were already collected as a part of their routine care between 01 January 2000 and 31 December 2022.
Age range
0 Years – 15 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Overall Number of New Cases Diagnosed With MLD During Year 2022
Timeframe: 1 year
Number of New Cases Diagnosed With MLD per Subgroups of Phenotype During Year 2022
Timeframe: 1 year
Overall Number of Participants With MLD Alive On 31 December 2022
Timeframe: 1 day
Number of Participants With MLD Alive On 31 December 2022 per Subgroups of Phenotype
Timeframe: 1 day
Overall Number of Participants With MLD Alive at Any Time During Year 2022
Timeframe: 1 year
Number of Participants With MLD Alive at Any Time During Year 2022 per Subgroups of Phenotype
Timeframe: 1 year